Opendata, web and dolomites

GlucoBeam SIGNED

GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Total Cost €


EC-Contrib. €






 GlucoBeam project word cloud

Explore the words cloud of the GlucoBeam project. It provides you a very rough idea of what is the project "GlucoBeam" about.

disposable    intake    world    scanning    innovation    diabetes    carefully    concentration    insulin    leverage    cornerstone    times    approx    droplet    strategy    relies    253    rsp    device    quality    treatment    patient    position    mellitus    people    ing    ultimately    aggregated    dm    glucobeam    levels    signals    acute    monitoring    balancing    population    cured    double    healthcare    uncomfortable    pain    minimum    raman    day    diabetic    commercialization    minimizing    collect    spectroscopy    invasive    painful    severe    individual    blood    foothold    turnover    faced    life    strip    health    secure    right    onto    refined    period    desired    optical    significantly    risk    detecting    million    leads    thereby    exercise    successful    added    electrochemical    complications    self    poor    finger    tissue    compliance    prick    sources    400    patients    post    avoiding    critical    30s    requiring    medium    therapy    digit    society    modern    savings    errors    extract    conventional    glucose    substances    lancet    proprietary    diet    empowering    billion    costly    repeating    market    smbg   

Project "GlucoBeam" data sheet

The following table provides information about the project.


Organization address
city: ODENSE S
postcode: 5260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 5˙219˙875 €
 EC max contribution 2˙348˙943 € (45%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RSP SYSTEMS A/S DK (ODENSE S) coordinator 2˙348˙943.00


 Project objective

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting over 400 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.


List of deliverables.
Project website Websites, patent fillings, videos etc. 2019-05-31 10:46:14

Take a look to the deliverables list in detail:  detailed list of GlucoBeam deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOBEAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOBEAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)


CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More